Joseph Mazar, PhD

Supplementary Figure 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 2 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 2 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 6 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 2 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Data from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Data from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 1 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 2 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 7 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 4 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 5 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

FIGURE 3 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 8 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 7 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

Supplementary Figure 8 from The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma <i>In Vivo</i> Models Confers a Major Survival Advantage in a CD24-dependent Manner; Unknown Source; (2024).

The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner; Cancer Research Communications; (2024).

Chaperonin containing TCP-1 (CCT/TRiC) is a novel therapeutic and diagnostic target for neuroblastoma.; Frontiers in oncology; (2022).

CD24 Expression Dampens the Basal Antiviral State in Human Neuroblastoma Cells and Enhances Permissivity to Zika Virus Infection.; Viruses; (2022).

MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance; Journal of Investigative Dermatology; (2021).

The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner; Anti-Cancer Agents in Medicinal Chemistry; (2020).

Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24; PLoS One; (2018).

Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24; PLOS ONE; (2018).

The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.; Oncotarget; (2017).

Nanoparticle delivery of Curcumin induces Cellular Hypoxia and ROS-mediated Apoptosis via modulation of Bcl-2/Bax in human Neuroblastoma; Nanoscale; (2017).

Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma; Nanoscale; (2017).

miR-211 functions as a metabolic switch in human melanoma cells.; Mol Cell Biol; (2016).

The long non-coding RNA SPRIGHTLY regulates cell proliferation in primary human melanocytes.; J Invest Dermatol; (2016).

Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection; J Mol Diagn; (2014).

The Functional Characterization of Long Noncoding RNA SPRY4-IT1 in Human Melanoma Cells; Oncotarget; (2014).

Genome-wide methylated CpG island profiles of melanoma cells reveal a melanoma coregulation network.; Nat Sci Rep; (2013).

Identification and Characterization of a Human Prostate Cancer Specific Long Non-Coding RNA; IJBBB; (2013).

The prodomain of the Bordetella two-partner secretion pathway protein FhaB remains intracellular yet affects the conformation of the mature C-terminal domain.; Mol Microbiol; (2012).

Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma; PLoS One; (2011).

Epigenetic regulation of microRNA-375 and its role in melanoma development in humans.; FEBS Lett; (2011).

The Melanoma Upregulated Long Noncoding RNA SPRY4-IT1 Modulates Apoptosis and Invasion; Cancer Res; (2011).

The regulation of miRNA-211 expression and its role in melanoma cell invasiveness.; PLoS One; (2010).

Protein-coding and non-coding gene expression analysis in differentiating human keratinocytes using a three-dimensional epidermal equivalent.; Mol Genet Genomics; (2010).

Natural-host animal models indicate functional interchangeability between the filamentous haemagglutinins of Bordetella pertussis and Bordetella bronchiseptica and reveal a role for the mature C-terminal domain, but not the RGD motif, during infection.; Mol Microbiol; (2009).

New insight into the molecular mechanisms of two-partner secretion; Trends Microbiol; (2007).

Topology and maturation of filamentous haemagglutinin suggest a new model for two-partner secretion; Mol Microbiol; (2006).